VANCOUVER, BC — December 5, 2025 — TempraMed Technologies Ltd. announced a major expansion into Western Europe through a new distribution partnership with Salomo Executive, enabling broad access to its temperature-controlled medication storage solutions across the Netherlands, Belgium, and Luxembourg. The collaboration will introduce TempraMed’s VIVI portfolio through leading pharmacy chains, wholesalers, diabetes-focused retailers, and medical distributors, marking a significant advancement in the company’s strategy to strengthen global medication-safety infrastructure.
Science Significance
TempraMed’s distribution expansion supports the wider adoption of patented, temperature-regulated technologies designed to protect the stability, potency, and safety of injectable medications, including insulin and other chronic-disease therapies. As temperature excursions are a major cause of medication degradation, the availability of scientifically engineered insulation systems that work continuously without power represents a meaningful step toward closing gaps in real-world medication handling. With space-grade insulation materials, FDA-registered construction, and 24/7 passive regulation, TempraMed’s solutions reflect a growing scientific commitment to safeguarding drug integrity beyond clinical and manufacturing environments.
Regulatory Significance
The partnership aligns strongly with Good Distribution Practice (GDP) expectations across Europe, where regulators emphasize proper storage, transport, and handling of temperature-sensitive medications. TempraMed’s products support patients and pharmacies in maintaining regulatory-aligned temperature control, reducing risk of non-compliance by preventing excursions outside labeled stability ranges. As climate variability and last-mile delivery pressures intensify, the expansion strengthens the ecosystem’s ability to meet regulatory requirements for medication protection across decentralized and outpatient settings. The agreement also reinforces the rising importance of device-based compliance tools in medication safety frameworks.
Business Significance
Advertisement
Securing access to the Benelux region represents a major commercial milestone, leveraging Salomo Executive’s extensive logistics network, 500+ pharmacy partners, and deep experience supporting leading pharmaceutical brands. This partnership enhances TempraMed’s market penetration at scale and accelerates its global growth trajectory, supported by a pipeline of new product launches and eight international patents. For a rapidly expanding diabetes market—where demand for reliable cold-chain and ambient protection continues to grow—this agreement strengthens TempraMed’s competitive position and underscores its evolution into a dominant player in temperature-controlled medical technology.
Patients’ Significance
With over 1.2 million people living with diabetes in the Netherlands and another 1.3 million with prediabetes, access to dependable medication-stability solutions is becoming increasingly essential. TempraMed’s devices provide everyday, travel-ready, and climate-resilient protection that supports adherence, safety, and therapeutic effectiveness. By making these tools widely available through pharmacies, specialists, and patient-focused retailers, the partnership directly improves patient empowerment and reduces the risk of medication failure due to improper storage—an issue that can lead to severe health complications and increased healthcare costs.
Policy Significance
The expansion reinforces policy momentum across Europe supporting safer medication-handling practices, particularly for chronic diseases requiring injectables. As healthcare systems emphasize patient self-management, home-based therapy, and reduced hospital burden, policymakers increasingly recognize the importance of validated device-based safeguards that ensure medication stability outside controlled facilities. TempraMed’s scalable presence in the Benelux region complements public-health strategies that prioritize chronic-disease resilience, health-system efficiency, and preventive adherence tools. The collaboration also illustrates how private-sector innovation supports evolving national and regional medication-safety objectives.
TempraMed’s partnership with Salomo Executive marks a significant advancement in securing safe, scalable access to temperature-controlled medication solutions across Western Europe. By combining scientific innovation, regulatory alignment, and extensive distribution capabilities, the collaboration strengthens the infrastructure needed to protect temperature-sensitive therapies throughout real-world use. As chronic disease prevalence rises and medication-safety expectations intensify, TempraMed’s expanded European footprint accelerates its mission to become the global standard in protecting life-saving medications in any environment.
Source: TempraMed Technologies Ltd. press release
